Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity
October 15 2018 - 9:00AM
Broadcast spot recognized at 2018 Medical
Marketing & Media (MM&M) Awards
MannKind Corporation (Nasdaq:MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with diseases such as diabetes
and pulmonary arterial hypertension, was recently awarded top
honors for its first Afrezza® TV commercial, “Unexpected Moments,”
at the Medical Marketing & Media (MM&M) awards ceremony
last week. The company worked with precisioneffect, a Boston-based
healthcare advertising agency, to produce the advertisement.
“Managing mealtime control is crucial in order
to help individuals living with diabetes optimize their outcomes,”
said Michael Castagna, CEO of MannKind Corporation. “Recent data
published from the STAT study showed that Afrezza is associated
with significant reductions in post-meal glucose excursions in
patients with type 1 diabetes compared to an injected rapid-acting
insulin. Our light-hearted ad, which showcases magical moments when
food appears seemingly out of nowhere, drives home the message that
it’s impossible to plan perfectly around meals. We are pleased that
we are bringing awareness to this topic and can showcase Afrezza as
an alternative to injected insulin at mealtimes.”
Since its launch in July 2017, the television ad
has contributed to increased interest in Afrezza, and a rise in
sales and new prescriptions in the markets it has aired.
“We are thrilled to have had the opportunity to
partner with MannKind and help spread awareness about Afrezza
through a campaign as unique as its product,” said Carolyn Morgan,
President, precisioneffect.
The Medical Marketing & Media annual awards
program is the premier healthcare advertising awards show to
recognize and champion both creativity and effectiveness in
healthcare marketing and communications.
The winning Afrezza TV advertisement can be seen
here: https://www.youtube.com/watch?v=INHz5-I35DA
About MannKind
CorporationMannKind Corporation (NASDAQ:MNKD) focuses
on the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently
commercializing Afrezza® (insulin human) Inhalation Powder, the
Company's first FDA-approved product and the only inhaled
rapid-acting mealtime insulin in the United States, where it
is available by prescription from pharmacies
nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs
field sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
Company Contact: Rose Alinaya SVP, Investor
Relations 818-661-5000 ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024